Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?
Hepatocellular carcinoma
MELD score
NPTX2
PTX3
Real-Time PCR
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
26
02
2021
accepted:
16
04
2021
pubmed:
28
4
2021
medline:
14
1
2022
entrez:
27
4
2021
Statut:
ppublish
Résumé
The long pentraxin (PTX) 3 and the neuronal pentraxin (NPTX) 2 has been found to exert pleiotropic roles in cancers due to their action in inflammation. However, the accurate clinical significance of PTX3 and NPTX2 in hepatocellular carcinoma (HCC), one of the commonest cancers in the world has not been well-defined. The aim of the study was to analyze the expression profile of PTX3 and NPTX2 in liver biopsies of HCV-positive HCC patients (liver recipients, LR, n = 14, age 59.4 ± 1.8 years) undergoing liver transplantation and in donors (LD, n = 14, age 62.1 ± 17.3 years), trying both to identify them as predictive biomarkers of clinical liver severity in HCC patients and to understand if they were mutually substitutable. The PTX3 and NPTX2 transcripts were significantly up regulated in HCC tissues (p = 0.004 and p = 0.02 LD vs. LR, respectively). Dividing patients following MELD score, PTX3 expression increased as a function of liver disease severity, while this trend was not observed for NPTX2, which mRNA level increased similarly in both MELD group, reaching the significance only in patients with MELD score < 9 (p = 0.01). A positive correlation was found between PTX3 and NPTX2 expression (p = 0.001; r = 0.69). This is the first study that concerns PTX3 and NPTX2 as a function of clinical severity from which emerged that both of them are unequivocally involved in HCC, but only PTX3 could be considered a staging marker in these HCV-related HCC patients, unlike NPTX2, which could only play a role as an inflammatory marker.
Identifiants
pubmed: 33905035
doi: 10.1007/s10238-021-00714-y
pii: 10.1007/s10238-021-00714-y
doi:
Substances chimiques
Biomarkers
0
Nerve Tissue Proteins
0
Serum Amyloid P-Component
0
neuronal pentraxin
0
PTX3 protein
148591-49-5
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
555-562Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Garlanda C, Bottazzi B, Bastone A, et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Ann Rev Immunol. 2005;23:337–66.
doi: 10.1146/annurev.immunol.23.021704.115756
Whitehead AS, Zahedi K, Rits M, Mortensen RF, Lelias JM. Mouse C-reactive protein. generation of cDNA clones, structural analysis and induction of mRNA during inflammation. Biochem J. 1990;266:283–90.
pubmed: 2310378
pmcid: 1131125
doi: 10.1042/bj2660283
Dowton SB, McGrew SD. Rat serum amyloid P component. Biochem J. 1990;270:571–85.
doi: 10.1042/bj2700553
Breviarios F, d’Aniellos EM, Golay J, et al. Interleukin-1-inducible genes in endothelial cells. J Biol Chem. 1992;267:22190–7.
doi: 10.1016/S0021-9258(18)41653-5
Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentraxin family of acute phase proteins. J Immunol. 1993;150:1804–12.
pubmed: 7679696
Schlimgen AK, Helms JA, Vogel H, Perin MS. Neuronal pentraxin, a secreted protein with homology to acute phase proteins of the immune system. Neuron. 1995;14:519–26.
pubmed: 7695898
doi: 10.1016/0896-6273(95)90308-9
Hsu YC, Perin MS. Human neuronal pentraxin II (NPTX2): conservation, genomic structure, and chromosomal localization. Genomics. 1995;28:220–7.
pubmed: 8530029
doi: 10.1006/geno.1995.1134
Tsui CC, Copeland NG, Gilbert DJ, Jenkins NA, Barnes C, Worley PF. Narp, a novel member of the pentraxin family, promotes neurite outgrowth and is dynamically regulated by neuronal activity. J Neurosci. 1996;16:2463–78.
pubmed: 8786423
pmcid: 6578758
doi: 10.1523/JNEUROSCI.16-08-02463.1996
Lee SJ, Wei M, Zhang C, et al. Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses. J Neurosci. 2017;37:1062–80.
pubmed: 27986928
pmcid: 5296791
doi: 10.1523/JNEUROSCI.2768-16.2016
Schwalbe RA, Dahlbäck B, Coe JE, Nelsestuen GL. Pentraxin family of proteins interact specifically with phosphorylcholine and/or phosphorylethanolamine. Biochemistry. 1992;31:4907–15.
pubmed: 1375509
doi: 10.1021/bi00135a023
Bonacina F, Baragetti A, Catapano AL, et al. Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. Mediators Inflamm. 2013;2013:725102.
pubmed: 23690668
pmcid: 3649691
doi: 10.1155/2013/725102
Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem. 1997;272:32817–23.
pubmed: 9407058
doi: 10.1074/jbc.272.52.32817
Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, Mantovani A. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016;64:1416–27.
pubmed: 26921689
pmcid: 5414834
doi: 10.1016/j.jhep.2016.02.029
Doni A, Stravalaci M, Inforzato A, et al. The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer. Front Immunol. 2019;10:712.
pubmed: 31019517
pmcid: 6459138
doi: 10.3389/fimmu.2019.00712
Chorny A, Casas-Recasens S, Sintes J, et al. The soluble pattern recognition receptor PTX3 links humoral innate and adaptive immune responses by helping marginal zone B cells. J Exp Med. 2016;213:2167–85.
pubmed: 27621420
pmcid: 5030794
doi: 10.1084/jem.20150282
Chang WC, Wu SL, Huang WC, et al. PTX3 gene activation in EGF-induced head and neck cancer cell metastasis. Oncotarget. 2015;6:7741–57.
pubmed: 25797258
pmcid: 4480713
doi: 10.18632/oncotarget.3482
Choi B, Lee EJ, Park YS, et al. Pentraxin-3 silencing suppresses gastric cancer-related inflammation by inhibiting chemotactic migration of macrophages. Anticancer Res. 2015;35:2663–8.
pubmed: 25964543
Choi B, Lee EJ, Shin MK, et al. Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic osteolysis by inducing long pentraxin 3. Oncotarget. 2016;7:55506–17.
pubmed: 27458153
pmcid: 5342432
doi: 10.18632/oncotarget.10747
Choi B, Lee EJ, Song DH, et al. Elevated Pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function. Oncotarget. 2014;5:481–92.
pubmed: 24457902
pmcid: 3964223
doi: 10.18632/oncotarget.1664
Locatelli M, Ferrero S, Martinelli Boneschi F, et al. The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. J Neuroimmunol. 2013;260:99–106.
pubmed: 23664694
doi: 10.1016/j.jneuroim.2013.04.009
Willeke F, Assad A, Findeisen P, et al. Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur J Cancer. 2006;42:2639–46.
pubmed: 16959485
doi: 10.1016/j.ejca.2006.05.035
Stallone G, Cormio L, Netti GS, et al. Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. Cancer Res. 2014;74:4230–8.
pubmed: 24950910
doi: 10.1158/0008-5472.CAN-14-0369
Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res. 2011;17:2395–9.
pubmed: 21257721
doi: 10.1158/1078-0432.CCR-10-3024
Ronca R, Giacomini A, Di Salle E, et al. Long-Pentraxin 3 derivative as a small-molecule fgf trap for cancer therapy. Cancer Cell. 2015;28:225–39.
pubmed: 26267536
doi: 10.1016/j.ccell.2015.07.002
Wang JX, He YL, Zhu ST, Yang S, Zhang ST. Aberrant methylation of the 3q25 tumor suppressor gene PTX3 in human esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:4225–30.
pubmed: 22072855
pmcid: 3208368
doi: 10.3748/wjg.v17.i37.4225
Bartolini A, Di Paolo D, Noghero A, et al. The neuronal pentraxin-2 pathway is an unrecognized target in human neuroblastoma, which also offers prognostic value in patients. Cancer Res. 2015;75:4265–71.
pubmed: 26294210
doi: 10.1158/0008-5472.CAN-15-0649
von Roemeling CA, Radisky DC, Marlow LA, et al. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res. 2014;74:4796–810.
doi: 10.1158/0008-5472.CAN-14-0210
Song T, Wang C, Guo C, Liu Q, Zheng X. Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition. J Cancer. 2018;9:2650–8.
pubmed: 30087705
pmcid: 6072810
doi: 10.7150/jca.25188
Feder S, Haberl EM, Spirk M, Weiss TS, Wiest R, Buechler C. Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients. Clin Exp Med. 2020;20:289–97.
pubmed: 32078718
pmcid: 7181432
doi: 10.1007/s10238-020-00617-4
Petruzziello A. Epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma. Open Virol J. 2018;12:26–32.
pubmed: 29541276
pmcid: 5842386
doi: 10.2174/1874357901812010026
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
pubmed: 18650914
doi: 10.1038/nature07205
Cabiati M, Gaggini M, De Simone P, Basta G, Gastaldelli A, Del Ry S. Assessment of RANKL/RANK/osteoprotegerin system expression in patients with hepatocellular carcinoma. Minerva Endocrinol. 2020. https://doi.org/10.23736/S0391-1977.20.03163-6 .
doi: 10.23736/S0391-1977.20.03163-6
Cabiati M, Gaggini M, Cesare MM, et al. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up. Cytokine. 2017;99:59–65.
pubmed: 28711012
doi: 10.1016/j.cyto.2017.07.004
Gaggini M, Cabiati M, Del Turco S, et al. Increased FNDC5/Irisin expression in human hepatocellular carcinoma. Peptides. 2017;88:62–6.
pubmed: 28012856
doi: 10.1016/j.peptides.2016.12.014
Wiesner RH, Edwards E, Freeman RA, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6.
pubmed: 12512033
doi: 10.1053/gast.2003.50016
Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–22.
pubmed: 19246619
doi: 10.1373/clinchem.2008.112797
De Simone P, Crocetti L, Pezzati D, et al. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2014;46:241–4.
pubmed: 24507059
doi: 10.1016/j.transproceed.2013.10.035
Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol. 2008;20:538–44.
pubmed: 18579363
doi: 10.1016/j.coi.2008.05.004
Ortega-Hernandez OD, Bassi N, Shoenfeld Y, Anaya JM. The Long Pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum. 2009;39:38–54.
pubmed: 18614204
doi: 10.1016/j.semarthrit.2008.03.006
Rajkovic I, Denes A, Allan SM, Pinteaux E. Emerging roles of the acute phase protein pentraxin-3 during central nervous system disorders. J Neuroimmunol. 2016;292:27–33.
pubmed: 26943955
doi: 10.1016/j.jneuroim.2015.12.007
Carmo RF, Aroucha D, Vasconcelos LR, Pereira LM, Moura P, Cavalcanti MS. Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV. J Viral Hepat. 2016;23:116–22.
pubmed: 26400151
doi: 10.1111/jvh.12472
Xu C, Tian G, Jiang C, et al. NPTX2 promotes colorectal cancer growth and liver metastasis by the activation of the canonical Wnt/ β -catenin pathway via FZD6. Cell Death Dis. 2019;10:217.
pubmed: 30833544
pmcid: 6399240
doi: 10.1038/s41419-019-1467-7
Narciso-Schiavon JL, Pereira JG, Silva TE, et al. Circulating levels of pentraxin-3 (PTX3) in patients with liver cirrhosis. Ann Hepatol. 2017;16:780–7.
pubmed: 28809733
doi: 10.5604/01.3001.0010.2789
Mantovani A, Ponzetta A, Inforzato A, Jaillon S. Innate immunity, inflammation and tumour progression: double-edged swords. J Intern Med. 2019;285:524–32.
pubmed: 30873708
pmcid: 7174018
doi: 10.1111/joim.12886
Ying TH, Lee CH, Chiou HL, et al. Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells. Sci Rep. 2016;6:29385.
pubmed: 27377307
pmcid: 4932528
doi: 10.1038/srep29385